Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) — Market Cap & Net Worth
Market Cap & Net Worth: Ironwood Pharmaceuticals Inc (IRWD)
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) has a market capitalization of $686.44 Million ($686.44 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10469 globally and #2777 in its home market, demonstrating a 11.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ironwood Pharmaceuticals Inc's stock price $4.23 by its total outstanding shares 164613406 (164.61 Million). See IRWD capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Ironwood Pharmaceuticals Inc Market Cap History: 2015 to 2026
Ironwood Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $1.60 Billion to $696.31 Million (-7.29% CAGR).
Index Memberships
Ironwood Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.03% | #290 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1078 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.04% | #173 of 263 |
Weight: Ironwood Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ironwood Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ironwood Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.87x
Ironwood Pharmaceuticals Inc's market cap is 1.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
23.10x
Ironwood Pharmaceuticals Inc's market cap is 23.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.11 Billion | $273.96 Million | -$81.71 Million | 7.69x | N/A |
| 2017 | $2.07 Billion | $298.28 Million | -$116.94 Million | 6.92x | N/A |
| 2018 | $1.43 Billion | $346.64 Million | -$282.37 Million | 4.12x | N/A |
| 2019 | $2.19 Billion | $428.41 Million | $21.50 Million | 5.11x | 101.88x |
| 2020 | $1.87 Billion | $389.52 Million | $106.18 Million | 4.81x | 17.66x |
| 2021 | $1.92 Billion | $413.75 Million | $528.45 Million | 4.64x | 3.63x |
| 2022 | $2.04 Billion | $410.60 Million | $175.06 Million | 4.97x | 11.65x |
| 2023 | $1.88 Billion | $442.74 Million | -$1.00 Billion | 4.25x | N/A |
| 2024 | $729.24 Million | $351.41 Million | $880.00K | 2.08x | 828.68x |
| 2025 | $554.75 Million | $296.15 Million | $24.02 Million | 1.87x | 23.10x |
Competitor Companies of IRWD by Market Capitalization
Companies near Ironwood Pharmaceuticals Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Ironwood Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Ironwood Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Ironwood Pharmaceuticals Inc's market cap moved from $1.60 Billion to $ 696.31 Million, with a yearly change of -7.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $696.31 Million | +25.52% |
| 2025 | $554.75 Million | -23.93% |
| 2024 | $729.24 Million | -61.28% |
| 2023 | $1.88 Billion | -7.67% |
| 2022 | $2.04 Billion | +6.26% |
| 2021 | $1.92 Billion | +2.37% |
| 2020 | $1.87 Billion | -14.43% |
| 2019 | $2.19 Billion | +53.49% |
| 2018 | $1.43 Billion | -30.89% |
| 2017 | $2.07 Billion | -1.96% |
| 2016 | $2.11 Billion | +31.92% |
| 2015 | $1.60 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Ironwood Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $686.44 Million USD |
| MoneyControl | $686.44 Million USD |
| MarketWatch | $686.44 Million USD |
| marketcap.company | $686.44 Million USD |
| Reuters | $686.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more